Global Live Attenuated Vaccines Market, By Product Type (Bacterial, Viral), Development (Tissue Culture, Embryonated Eggs, Live Animals), Indication (Tuberculosis, Measles, Rotavirus, Yellow Fever, Oral Polio, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2031.
Live Attenuated Vaccines Market Analysis and Size
The increase in the number of people suffering from infectious diseases across the globe acts as one of the major factors driving the growth of the live attenuated vaccines market. The rise in demand for disease-specific novel treatment for the various disease complications, and the increase in demand for the program aiming to prevent the spread of transmission and, also to alleviate the suffering accelerate the market growth. The rise in the number of clinical trials conducted by many pharmaceutical industries, and the initiatives by public and private organizations towards developing enhanced therapies further influence the market.
Data Bridge Market Research analyzes that the global live attenuated vaccines market which was USD 29,910.12 million in 2023, is expected to reach USD 42,145.42 million by 2031, and is expected to undergo a CAGR of 12.3% during the forecast period of 2024 to 2031. “Bacterial” dominates the product type segment of the market due to rising demand for live attenuated vaccines. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Live Attenuated Vaccines Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product Type (Bacterial, Viral), Development (Tissue Culture, Embryonated Eggs, Live Animals), Indication (Tuberculosis, Measles, Rotavirus, Yellow Fever, Oral Polio, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Belgium, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa.
|
|
Market Players Covered
|
GlaxoSmithKline, plc. (U.K.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), MedImmune, LLC (U.S.), Sanofi (France), Serum Institute of India Pvt. Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
Vaccines created by reducing the virulence of pathogens are known as live attenuated vaccines (LAV). These pathogens are weakened under laboratory conditions. The vaccine triggers a potent immune response against infectious diseases. They initiate memory cell production in order to respond to the pathogen that previously invaded the body.
Global Live Attenuated Vaccines Market Dynamics
Drivers
- Growing Emphasis on Preventive Healthcare
Live attenuated vaccines play a pivotal role in preventive healthcare strategies, witnessing increased adoption worldwide. Government initiatives promoting immunization and the prioritization of disease prevention contribute significantly to the demand for live attenuated vaccines. These vaccines offer robust immune responses, long-lasting protection, and cost-effectiveness, driving their usage for preventing various infectious diseases.
- Expanding Vaccination Programs
The expansion of national and international vaccination programs globally fuels the demand for live attenuated vaccines. Initiatives by organizations like WHO and UNICEF focus on increasing vaccine coverage, especially in developing nations, thereby driving the market growth. The incorporation of live attenuated vaccines in routine immunization schedules and mass vaccination campaigns further boosts their market demand.
- Prevalence of Infectious Diseases
The persistent prevalence of infectious diseases, such as measles, mumps, rubella, and tuberculosis, among others, drives the demand for live attenuated vaccines. These vaccines are highly effective in preventing infections caused by various pathogens, making them essential in disease control and eradication efforts. The ongoing global burden of infectious diseases continues to propel the market for live attenuated vaccines.
Opportunity
- Technological Advancements in Vaccine Development
Continuous advancements in biotechnology and vaccine development techniques enhance the production and efficacy of live attenuated vaccines. Innovations such as reverse genetics, molecular biology tools, and improved manufacturing processes contribute to the development of safer and more effective vaccines. These technological advancements foster the growth of the live attenuated vaccines market by ensuring better vaccine quality and potency.
Restraints/Challenges
- Safety Concerns and Side Effects
Safety concerns associated with live attenuated vaccines pose a significant restraint to their market growth. While generally safe, these vaccines may cause adverse reactions in certain individuals, such as immunocompromised individuals or pregnant women. Rare instances of vaccine-associated diseases or complications deter some individuals and healthcare providers from opting for live attenuated vaccines.
- Storage and Transportation Challenges
Live attenuated vaccines require stringent storage and transportation conditions, including specific temperature controls to maintain their efficacy. The need for cold chain logistics poses logistical challenges, especially in regions with inadequate infrastructure or limited access to refrigeration facilities. Storage requirements increase operational costs and pose challenges in maintaining vaccine potency during distribution.
This live attenuated vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the live attenuated vaccines market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In May 2022, Dr. Reddy's laboratories launched the Ketorolac Tromethamine tablets USP, 10 mg, in the United States market. Ketorolac Tromethamine tablets, 10 mg, is a non-steroidal anti-inflammatory drug indicated for the short-term management of moderately severe acute pain
Global Live Attenuated Vaccines Market Scope
The live attenuated vaccines market is segmented on the basis of product type, development, indication, mode of administration, distribution channel, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Bacterial
- Viral
Development
- Tissue Culture
- Embryonated Eggs
- Live Animals
Indication
- Tuberculosis
- Measles
- Rotavirus
- Yellow Fever
- Oral Polio
- Others
Mode of Administration
- Oral
- Injectable
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Live Attenuated Vaccines Market Regional Analysis/Insights
The live attenuated vaccines market is analyzed and market size insights and trends are provided by country, product type, development, indication, mode of administration, distribution channel and end user as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Belgium, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands Switzerland, rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and rest of Middle East and Africa.
North America is expected to dominate the market due to the increase in the expenditure for research and development proficiencies, increasing government initiatives, and improved healthcare infrastructure in various countries.
Asia-Pacific is expected to exhibit the highest growth rate in the market during the forecast period of 2024 to 2031 due to the increasing government expenditure on the healthcare sector and rising technological advancements and initiatives by the government.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The live attenuated vaccines market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for live attenuated vaccines market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the live attenuated vaccines market. The data is available for historic period 2016-2021.
Competitive Landscape and Global Live Attenuated Vaccines Market Share Analysis
The live attenuated vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the live attenuated vaccines market.
Some of the major players operating in the live attenuated vaccines market are:
- GlaxoSmithKline, plc. (U.K.)
- Merck & Co. (U.S.)
- Pfizer, Inc. (U.S.)
- Astellas Pharma Inc. (Japan)
- Johnson & Johnson (U.S.)
- CSL Limited (Australia)
- Emergent BioSolutions, Inc. (U.S.)
- MedImmune, LLC (U.S.)
- Sanofi (France)
- Serum Institute of India Pvt. Ltd. (India)
SKU-